Lipids are thought to play an important role in the aggregation of alpha-synuclein and are found in Lewy bodies, the hallmark of Parkinson’s disease. Research to date on the molecular interaction between lipids and alpha-synuclein—utilizing experimental methods such as nuclear magnetic resonance, electron paramagnetic resonance, and neutron reflectivity—has mostly been carried out at relatively low concentrations of alpha-synuclein.
A recently published study in Neurology showed that higher levels of physical activity were associated with a lower incidence of Parkinson’s Disease (PD) in a large cohort of women.
A recently published study in Neurology showed that higher levels of physical activity were associated with a lower incidence of Parkinson’s Disease (PD) in a large cohort of women.
A recently published study in Neurology showed that higher levels of physical activity were associated with a lower incidence of Parkinson’s Disease (PD) in a large cohort of women.
Vaxxinity, Inc. announced that its investigational synthetic peptide vaccine for Parkinson’s, UB-312, met the primary endpoints of a Phase 1 clinical trial designed to assess its tolerability and efficacy in creating an antibody response against toxic aggregates of alpha-synuclein.
Enterin Inc., a biopharmaceutical company based in Philadelphia, is aiming to become the first to develop a treatment that targets the gut-brain axis in patients with neurodegenerative disease.
In a poster presented at the American Academy of Neurology 2023 Annual Meeting, researchers from Hartford HealthCare compared the utility of skin biopsy testing, using the Syn-One Test from CND Life Sciences, to DaTscan for diagnosing synucleinopathies.
A study published this week in NJP Parkinson’s Disease compared two methods of detecting alpha-synuclein in patients with early-stage idiopathic REM sleep behavior disorder (iRBD), a neurodegenerative disorder that often precedes the development of Parkinson’s disease and other neurodegenerative diseases.
Research published last month in the New England Journal of Medicine demonstrated that a focused ultrasound procedure improved motor function in patients with Parkinson’s disease.
San Diego-based Ryne Biotechnology announced last week that it has received a $4 million Clinical Stage Research Program grant from the California Institute for Regenerative Medicine (CIRM) to move RNDP-0001 into clinical testing.